Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : Lilly executive accused of rewriting documents to downplay issues at Covid drug plant

05/05/2021 | 11:01am EDT

Eli Lilly & Co employees have accused a factory executive of changing documents required by government regulators to downplay serious quality control problems.

The accusations are alleged to have happened at the drug maker’s US plant which produces Covid-19 treatment, according to an internal complaint.

The unsigned report, reviewed by Reuters after being filed through the confidential employee complaint system, is the latest sign of manufacturing issues at the drug giant.

It says that the executive rewrote findings by technical experts at the plant, which has been under investigation, to make the conclusions more favourable to the firm.

Read more: Donald Trump’s Facebook ban upheld by oversight board

The confidential source said the findings involved the production of drugs, including the company’s government-funded Covid-19 therapy.

This antibody treatment has been authorised by the US Food and Drug Administration (FDA) for emergency use in combination with a drug for Covid infections in high-risk patients.

Back in March, FDA inspectors found several manufacturing lapses at a Lilly facility in Indianapolis that bottles the Covid-19 therapy.

Problems at the plant included poor sanitation and quality control procedures, according to a preliminary FDA report.

Meanwhile, the company’s chief financial officer resigned in February over what the firm called “inappropriate personal communications” with an employee.

The troubles at the two factories, along with a succession of internal complaints in recent years, deepen the issues facing Eli Lilly & Co, one of the biggest drug makers in the world.

Read more: Britain to scrap EU rule giving choice of clearer in derivatives

The post Lilly executive accused of rewriting documents to downplay issues at Covid drug plant appeared first on CityAM.

© City AM, source Newspaper

All news about ELI LILLY AND COMPANY
02:53aALEMBIC PHARMACEUTICALSá : JV Gets US FDA Nod for Testosterone Topical Solution
MT
06/15ELI LILLY ANDá : JPMorgan Adjusts Price Target on Eli Lilly to $260 From $240, M..
MT
06/15ELI LILLY ANDá : to Compare Migraine Drugs Emgality, Nurtec ODT in Phase 4 Study
MT
06/15AstraZeneca antibody cocktail fails to prevent COVID-19 in large trial
RE
06/14ELI LILLY ANDá : Significant Insider Selling Continues at Eli Lilly (LLY)
MT
06/14ELI LILLY ANDá : Lilly to Participate in Guggenheim Biopharma Strategy Series
PR
06/14ELI LILLY ANDá : Bernstein Adjusts Price Target on Eli Lilly to $250 From $205, ..
MT
06/14ELI LILLY ANDá : Goldman Sachs Adjusts Eli Lilly's Price Target to $270 From $25..
MT
06/14Fiserv Appoints Wafaa Mamilli to Board of Directors
AQ
06/11ELI LILLY ANDá : Significant Insider Selling in Shares of Eli Lilly (LLY) Contin..
MT
More news
Financials (USD)
Sales 2021 27 273 M - -
Net income 2021 6 537 M - -
Net Debt 2021 11 213 M - -
P/E ratio 2021 30,3x
Yield 2021 1,51%
Capitalization 201 B 201 B -
EV / Sales 2021 7,77x
EV / Sales 2022 7,55x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 222,09 $
Last Close Price 220,76 $
Spread / Highest target 22,3%
Spread / Average Target 0,60%
Spread / Lowest Target -20,7%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY32.39%203 185
JOHNSON & JOHNSON4.52%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.7.55%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.8.10%204 582